

**Remarks:**

Claims 1-25 were pending. Applicants have herein canceled claims 1-25 without prejudice and added new claims 26-72. This amendment does not involve any issue of new matter. The claims are fully supported by the application as filed.

The Examiner has required restriction between:

Group I, claims 1-24, allegedly drawn to slow release formulation and method of making the formulation; and

Group II, claim 25 allegedly drawn to method of conducting pharmaceutical business.


The Examiner is also requiring a species election. The Examiner is requiring election of a species of a biologically active molecule and an organic solvent.

In response, applicants respectfully elect with traverse Examiner's Group I. Accordingly, applicants respectfully request examination of new claims 26-72. In addition, applicants provisionally elect with traverse the following species for search purposes: (a) biologically active molecule: interferon; and (b) organic solvent: n-propanol.

Applicant believes no fee other than the \$198.00 fee for additional claims is due with this response. However, if any additional fee is due, please charge our Deposit Account No. 18-1945, under Order No. PBLI-P01-010 from which the undersigned is authorized to draw.

Dated: September 15, 2003

Respectfully submitted,

By   
Spencer H. Schneider  
Registration No.: 45,923  
ROPES & GRAY LLP  
45 Rockefeller Plaza  
New York, NY 10111  
(212) 497-3615  
(212) 497-3650 (Fax)  
Attorneys/Agents For Applicant